Insulin glargine (Basaglar) vs Insulin glargine (Toujeo)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline

Insulin glargine (Basaglar)

Marketed by Eli Lilly and partners

Approved in Type 2 Diabetespeptide
Partial signal

NCT01421459 · Phase 3 · completed

The study was randomized, triple-blind, and active-controlled, with 759 participants, but its primary endpoint was HbA1c, a laboratory surrogate rather than a hard clinical outcome. The prespecified non-inferiority comparison was met: the 95% confidence interval for the treatment difference remained below the +0.4% margin.

Reported efficacy

Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062) (met)

Result source: NCT03338010

Insulin glargine (Toujeo)

Marketed by Sanofi

Approved in Type 2 Diabetespeptide
Partial signal

NCT01499082 · Phase 3 · completed

The trial was large and randomized, with an active insulin glargine comparator, and its primary HbA1c endpoint was a hard clinical treatment measure that met the prespecified non-inferiority margin. However, treatment was open-label rather than double-blinded, so the evidence is considered moderate despite the favorable non-inferiority result.

Reported efficacy

Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061) (met)

Result source: NCT01499082

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointInsulin glargine (Basaglar)Insulin glargine (Toujeo)
HbA1c, change-1.3% vs -1.3%vs Lantuswk 24 · n 369NCT01421459
9 other results
  • -1.3% vs -1.2% wk 24 · n 226 · Phase 3 · primary NCT02302716
  • -1.3% vs -1.2% wk 24 · n 334 · Phase 3 · primary NCT03338010
  • -1.3% vs -1.4% wk 24 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.2% wk 24 · n 334 · Phase 3 · secondary NCT03338010
  • -1.3% vs -1.4% wk 20 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.3% wk 16 · n 369 · Phase 3 · secondary NCT01421459
  • -1.1% vs -1.1% wk 12 · n 369 · Phase 3 · secondary NCT01421459
  • -0.9% vs -0.9% wk 8 · n 369 · Phase 3 · secondary NCT01421459
  • -0.5% vs -0.5% wk 4 · n 369 · Phase 3 · secondary NCT01421459
—Not reported
Body weight, change (kg)1.9 vs 2.2vs Lantuswk 24 · n 370NCT01421459
7 other results
  • 2.3 vs 1.7 wk 24 · n 229 · Phase 3 · secondary NCT02302716
  • 1.1 vs 1.2 wk 24 · n 334 · Phase 3 · secondary NCT03338010
  • 1.7 vs 2.2 wk 20 · n 370 · Phase 3 · secondary NCT01421459
  • 1.6 vs 1.9 wk 16 · n 370 · Phase 3 · secondary NCT01421459
  • 1.3 vs 1.4 wk 12 · n 370 · Phase 3 · secondary NCT01421459
  • 1.0 vs 1.2 wk 8 · n 370 · Phase 3 · secondary NCT01421459
  • 0.3 vs 0.5 wk 4 · n 370 · Phase 3 · secondary NCT01421459
—Not reported
HbA1c below 7%43.7% vs 44.9%vs Lantus®wk 24 · n 334NCT03338010—Not reported
Fasting plasma glucose, change—Not reported—Not reported
3-point MACE (% with event)—Not reported—Not reported

HbA1c, change

Insulin glargine (Basaglar)
-1.3% vs -1.3%vs Lantuswk 24 · n 369NCT01421459
9 other results
  • -1.3% vs -1.2% wk 24 · n 226 · Phase 3 · primary NCT02302716
  • -1.3% vs -1.2% wk 24 · n 334 · Phase 3 · primary NCT03338010
  • -1.3% vs -1.4% wk 24 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.2% wk 24 · n 334 · Phase 3 · secondary NCT03338010
  • -1.3% vs -1.4% wk 20 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.3% wk 16 · n 369 · Phase 3 · secondary NCT01421459
  • -1.1% vs -1.1% wk 12 · n 369 · Phase 3 · secondary NCT01421459
  • -0.9% vs -0.9% wk 8 · n 369 · Phase 3 · secondary NCT01421459
  • -0.5% vs -0.5% wk 4 · n 369 · Phase 3 · secondary NCT01421459
Insulin glargine (Toujeo)
—Not reported

Body weight, change (kg)

Insulin glargine (Basaglar)
1.9 vs 2.2vs Lantuswk 24 · n 370NCT01421459
7 other results
  • 2.3 vs 1.7 wk 24 · n 229 · Phase 3 · secondary NCT02302716
  • 1.1 vs 1.2 wk 24 · n 334 · Phase 3 · secondary NCT03338010
  • 1.7 vs 2.2 wk 20 · n 370 · Phase 3 · secondary NCT01421459
  • 1.6 vs 1.9 wk 16 · n 370 · Phase 3 · secondary NCT01421459
  • 1.3 vs 1.4 wk 12 · n 370 · Phase 3 · secondary NCT01421459
  • 1.0 vs 1.2 wk 8 · n 370 · Phase 3 · secondary NCT01421459
  • 0.3 vs 0.5 wk 4 · n 370 · Phase 3 · secondary NCT01421459
Insulin glargine (Toujeo)
—Not reported

HbA1c below 7%

Insulin glargine (Basaglar)
43.7% vs 44.9%vs Lantus®wk 24 · n 334NCT03338010
Insulin glargine (Toujeo)
—Not reported

Fasting plasma glucose, change

Insulin glargine (Basaglar)
—Not reported
Insulin glargine (Toujeo)
—Not reported

3-point MACE (% with event)

Insulin glargine (Basaglar)
—Not reported
Insulin glargine (Toujeo)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. Insulin glargine (Basaglar): 6 of 6 rows · Insulin glargine (Toujeo): 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricInsulin glargine (Basaglar)Insulin glargine (Toujeo)
HbA1c
absolute change · percentage points
No placebo or comparator arm
-0.86% (n=259) @ 24wka,b,c
NCT04153981 · Phase 4 · registry result, not featured evidence
-1.29% (n=1651) @ 52wka,b,c
NCT02451137 · Phase 4 · registry result, not featured evidence
Weight
absolute change · kg
No placebo or comparator arm
-0.5 kg @ 24wka,b,c
NCT04153981 · Phase 4 · registry result, not featured evidence
1.51 kg @ 52wka,b,c
NCT02451137 · Phase 4 · registry result, not featured evidence
Dropout rate
11.9%d
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
7.6%
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
6.4%
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
28.3%
NCT04153981 · Phase 4 · registry result, not featured evidence
14.8%e
NCT03013985 · Phase 4 · registry result, not featured evidence
show 1 more result
14.9%
NCT02451137 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs
1.6%d
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
0.4%
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.8%
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—
NCT04153981 · Phase 4 · registry result, not featured evidence
—e
NCT03013985 · Phase 4 · registry result, not featured evidence
show 1 more result
2.6%
NCT02451137 · Phase 4 · registry result, not featured evidence
Serious AEs
4%d
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
4%
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.8%
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0.4%
NCT04153981 · Phase 4 · registry result, not featured evidence
19.4%e
NCT03013985 · Phase 4 · registry result, not featured evidence
show 1 more result
9.8%
NCT02451137 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs
d
nasopharyngitis 5.6%
upper respiratory tract infection 5.1%
abnormal weight gain 2.7%
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
nasopharyngitis 7.2%
upper respiratory tract infection 4%
weight increased 3.2%
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
upper respiratory tract infection 20.3%
hypertension 5.6%
injection site pain 4.2%
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
anaemia 1.9%
cough 0.4%
hyperglycaemia 0.4%
NCT04153981 · Phase 4 · registry result, not featured evidence
e
trauma 3.7%
cough 0.9%
gastroparesis 0.9%
NCT03013985 · Phase 4 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cAssessment timepoints differ: 24 weeks versus 52 weeks.
  4. dPopulation comparability has not been reviewed for 1 of these studies.
  5. ePopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Insulin glargine (Basaglar)

HbA1c -1.286% (n=369) vs -1.338% (n=375) Lantus @ 24wk
absolute change · percentage points
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 9 more results
-0.452% (n=369) vs -0.481% (n=375) Lantus @ 4wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.871% (n=369) vs -0.866% (n=375) Lantus @ 8wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.134% (n=369) vs -1.143% (n=375) Lantus @ 12wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.265% (n=369) vs -1.321% (n=375) Lantus @ 16wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.294% (n=369) vs -1.379% (n=375) Lantus @ 20wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.336% (n=369) vs -1.438% (n=375) Lantus @ 24wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.25% (n=226) vs -1.22% (n=223) LANTUS® @ 24wk
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.27% (n=334) vs -1.23% (n=158) Lantus® @ 24wk
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-1.27% (n=334) vs -1.23% (n=158) Lantus® @ 24wk
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Weight 0.292 vs 0.526 Lantus kg @ 4wk
absolute change · kg
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 7 more results
0.999 vs 1.152 Lantus kg @ 8wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.271 vs 1.44 Lantus kg @ 12wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.55 vs 1.918 Lantus kg @ 16wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.734 vs 2.234 Lantus kg @ 20wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.914 vs 2.175 Lantus kg @ 24wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.3 vs 1.7 LANTUS® kg @ 24wk
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.1 vs 1.2 Lantus® kg @ 24wk
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
HbA1c Less Than 7% 43.7% (n=334) vs 44.9% (n=158) Lantus® @ 24wk
responder rate · % of participants
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
HbA1c Less Than or Equal to 6.5 23.4% (n=334) vs 16.5% (n=158) Lantus® @ 24wk
responder rate · % of participants
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
SMBG 7-point Change mg/dL -38.7 mg @ 24wk
absolute change · mg
No placebo or comparator arm
Blood glucose concentration before breakfast
NCT04153981 · Phase 4 · registry result, not featured evidence

Insulin glargine (Toujeo)

Daily Glucose mg/dL 10.32 vs 10.21 Glargine U100 mmol/L
absolute value · mmol/L
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 186 mg/dL as posted
show 6 more results
9.52 vs 9.13 Glargine U100 mmol/L @ 12wk*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 171.6 mg/dL as posted
8.33 vs 7.46 Glargine U100 mmol/L @ 12wk*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 150 mg/dL as posted
8.45 vs 8.64 Glargine U100 mmol/L @ 12wk*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 152.3 mg/dL as posted
9.42 vs 10.92 Glargine U100 mmol/L*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 169.71 mg/dL as posted
10.74 vs 10.75 Glargine U100 mmol/L*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 193.53 mg/dL as posted
10.46 vs 9.69 Glargine U100 mmol/L*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 188.46 mg/dL as posted
Time in Range 50.3% (n=92) vs 54.9% (n=84) Glargine U100 @ 12wk
absolute value · percentage points
NCT03013985 · Phase 4 · registry result, not featured evidence
Hypoglycemia Event Incidence 8.7% (n=92) vs 9.5% (n=84) Glargine U100 @ 12wk
responder rate · % of participants
NCT03013985 · Phase 4 · registry result, not featured evidence
Severe Hypoglycemia Event Incidence 0% (n=92) vs 6% (n=84) Glargine U100 @ 12wk
responder rate · % of participants
NCT03013985 · Phase 4 · registry result, not featured evidence
HbA1c Target Attainment Without Hypoglycemia 31.3% (n=1651) @ 26wk
responder rate · % of participants
No placebo or comparator arm
NCT02451137 · Phase 4 · registry result, not featured evidence
show 1 more result
37.3% (n=1651) @ 26wk
NCT02451137 · Phase 4 · registry result, not featured evidence
Fasting Plasma Glucose -2.71 mmol/L @ 26wk
absolute change · mmol/L
No placebo or comparator arm
NCT02451137 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -48.9 mg/dL as posted
show 1 more result
-2.66 mmol/L @ 52wk*
NCT02451137 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -48 mg/dL as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin glargine (Basaglar)'s landscape · Insulin glargine (Toujeo)'s landscape